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Abstract 
The  human  equilibrative  nucleoside  trans-
porter 1 (hENT1) is the major means by which
gemcitabine  enters  human  cells;  recent  evi-
dence exists that hENT1 is expressed in carcino-
ma of the ampulla of Vater and that it should be
considered as a molecular prognostic marker for
patients with resected ampullary cancer. Aim of
the present study is to evaluate the variations of
hENT1 expression in ampullary carcinomas and
to  correlate  such  variations  with  histological
subtypes  and  clinicopathological  parameters.
Forty-one ampullary carcinomas were histologi-
cally classified into intestinal, pancreaticobiliary
and unusual types. hENT1 and Ki67 expression
were evaluated by immunohistochemistry, and
apoptotic cells were identified by the terminal
deoxynucleotidyl transferase mediated deoxyuri-
dine  triphosphate  biotin  nick  end  labelling
(TUNEL)  method.  hENT1  overexpression  was
detected in 63.4% ampullary carcinomas. A sig-
nificant difference in terms of hENT1 and Ki67
expression  was  found  between  intestinal  vs.
pancreaticobiliary  types  (P=0.03  and  P=0.009
respectively). Moreover, a significant statistical
positive correlation was found between apoptot-
ic and proliferative Index (P=0.036), while no
significant  correlation  was  found  between
hENT1  and  apoptosis.  Our  results  on  hENT1
expression  suggest  that  classification  of
ampullary carcinoma by morphological subtypes
may represent an additional tool in prospective
clinical trials aimed at examining treatment effi-
cacy; in addition, data obtained from Ki67 and
TUNEL suggest a key role of hENT1 in tumour
growth of ampullary carcinoma.
Introduction
The  ampulla  of  Vater  consists  of  papilla,
common  channel,  distal  common  bile  duct
(ampullo-biliary portion), and the distal main
pancreatic  duct  (ampullo-pancreatical  por-
tion).  The  papilla  is  covered  by  intestinal
mucosa, while the inner parts of the ampulla
are  lined  by  a  simple  mucinous  epithelium
similar to that of the pancreaticobiliary tree.
1,2
Therefore,  ampullary  carcinomas  may  arise
from  two  different  types  of  mucosa,  which
might  reflect  the  broad  histomorphological
spectrum of these tumors.
3 Kimura et al., for
the first time, have distinguished pancreatico-
biliary  type  and  intestinal  type  of  ampullary
carcinoma.
2 In  2000,  Albores-Saavedra  et  al.
defined  the  pancreaticobiliary  and  intestinal
types as main types and added the so-called
“unusual types”.
4
The adjuvant therapy for resected ampullary
carcinoma is poorly studied due, in part, to the
rarity of the cancer. Gemcitabine (Gemzar, Eli
Lilly,  Indianapolis,  In,  USA)  is  a  pyrimidine
nucleoside  analogue  that  is  the  most  single
effective agent in the chemotherapy of pancre-
atic adenocarcinoma
5 and appears to be a rea-
sonable alternative to best supportive care in
the treatment of advanced biliary tract cancers,
on the basis of encouraging results in non-ran-
domized clinical studies.
6,7 The human equili-
brative nucleoside transporter 1 (hENT1) is an
ubiquitous  specialized  plasma  membrane
nucleoside transporters protein and it repre-
sents the major means by which gemcitabine
enters  human  cells.
8,9 Tissue  expression  of
hENT1  protein  can  be  evaluated  using
immunohistochemistry;  by  this  method,  its
amount and distribution has been assessed in
a number of malignant and benign tissues.
10-14
In  a  recent  report,  we  demonstrated  that
hENT1  is  expressed  in  carcinomas  of  the
ampulla of Vater and should be considered a
molecular prognostic marker for patients with
resected  ampullary  cancer.
15 Moreover,  in  a
recent  prospective  randomized  trial,  hENT1
protein  expression  was  associated  with
increased  overall  survival  and  disease-free
survival  in  pancreatic  cancer  patients  who
received  gemcitabine.
16 Given  the  high  vari-
ability  of  histological  presentation  of
ampullary carcinomas, we aimed at carefully
assessing hENT1 expression in the different
histotypes of the tumour, as well as its rela-
tionship with the proliferation and apoptosis
indices (respectively PI and AI). This was per-
formed  by  means  of  immunohistochemistry
and  TUNEL  methods  on  surgical  specimens
from radically resected ampullary carcinomas. 
Materials and Methods
Specimen acquisition and histologi-
cal examination
To  be  eligible  for  the  study,  each  subject
underwent surgical resection for tumours of
ampullary origin with curative intent, and only
patients without known residual disease were
analyzed.  The  procedures  followed  were  in
accordance with the ethical standards of the
local responsible committee on human experi-
mentation  (Campus  Bio-Medico  University,
Rome, Italy). All specimens underwent gross
anatomical examination according to the pro-
cedure  described  by  Rosai  including  evalua-
tion  of  all  anatomic  structures  (pancreatic
duct, ampulla of Vater, common bile duct, pan-
creatic  head).
17 All  tumours  included  in  the
study were limited to the ampulla, or were pri-
marily located in the ampulla with secondarily
spreading  into  the  neighbouring  structures.
TNM  (tumour  local  extension,  nodes  and
metastasis  status)  classification  was  re-
assessed  following  the  International  Union
Against  Cancer  criteria.
18 Histological  slides
were  independently  re-examined  by  two
pathologists  and  all  tumours  were  classified
histologically  as  intestinal-type,  pancreatico-
biliary-type  and  unusual-type.
4 Agreement  in
histological  evaluation  between  the  two
observers was >90%. In cases of disagreement,
a final decision was determined by consensus
after re-examination.
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Immunohistochemistry
The  specimens  were  fixed  in  4%  neutral-
buffered  formaldehyde  and  routinely  embed-
ded in paraffin. Based on the quality of the
morphologic  preservation  of  all  available
haematoxylin and eosin stained slides of the
surgical specimen sections, we selected one
paraffin  block  for  each  case.  Immunohi  -
stochemical staining was performed as previ-
ously  described.
16 Briefly,  representative
tumour  blocks  were  sectioned  at  3  µm  and
processed by the streptoavidin-biotin method.
Incubation  was  performed  in  a  humidified
chamber  overnight  at  4°C  with  anti-hENT1
mouse  monoclonal  antibody  (dilution: 
10  μg/mL),  developed  and  characterized  as
previously  described,
10 and  with  anti-Ki-67
mouse  mAb  (1:50,  clone  MIB-1,  DAKO,
Cytomation  Inc.,  Carpinteria,  CA,  USA).
Sections were then incubated with goat anti-
mouse  dextran  conjugate  (DAKO  Envision,
DAKO, Cytomation Inc., Carpinteria, CA, USA)
for  30  min.  3-3’-diaminobenzidine  (DAB,
DAKO, Cytomation Inc., Carpinteria, CA, USA)
was  used  as  chromogen.  Negative  control
slides  processed  without  primary  antibody
were included for each staining. 
Scoring for hENT1 was based on the relative
staining  intensity  of  the  ampullary  tumour
when compared to normal membrane hENT1
staining of cells of the islets of Langerhans and
lymphocytes, which served as internal control.
Staining intensity was graded as absent (0),
positive,  less  intense  than  internal  control
(1+), positive, same intensity as internal con-
trol (2+), positive, more intense than internal
control (3+). In samples with varying staining
intensities of hENT1, the percentages of each
staining  intensity  were  recorded.  hENT1
expression was considered “significant” when
staining intensity of 2+ and 3+ was present in
the  majority  of  tumour  tissue  (≥50%  of  the
tumour cells).  Ki-67 staining was evaluated by
counting  the  number  of  positively  stained
nuclei  in  at  least  1000  tumour  cells;
immunoreactivity was graded by the percent-
age of nuclear staining (defined as prolifera-
tive index).
Detection of apoptosis
Apoptotic cells were identified by the TUNEL
method using the ApopTag TUNEL kit (Oncor,
Gaithersburg, MD, USA) according to the man-
ufacturer’s  instructions.  Dewaxed  and  rehy-
drated specimens were incubated in proteinase
K (40 mg/mL) for one hour at 37˚C, and were
then  treated  with  3%  H2O2 in  methanol  for 
30 min at room temperature. After adding equi-
libration buffer for 5 min at room temperature,
the  terminal  deoxynucleotidyl  transferase
enzyme  was  pipetted  onto  the  sections  and
incubated at 37˚C for 2 hours. The reaction was
stopped  by  incubating  the  sections  in  stop
buffer for 30 min at 37˚C. Anti-digoxigenin per-
oxidase was added to the slides, followed by
incubation  for  30  min  at  37˚C.  Slides  were
stained with diaminobenzine for 10 min and
counterstained with haematoxylin. The num-
ber of apoptotic bodies was expressed in rela-
tion to the total number of cells within at least
1000 tumour cells counted in high-power fields.
Strict  criteria  were  used  to  define  a  cell  as
apoptotic on TUNEL stained sections, i.e. the
presence of a condensed and often fragmented
nucleus together with a surrounding halo. Cells
containing weakly to moderate TUNEL positive
nuclei in the absence of these additional mor-
phological features were not assessed as apop-
totic. The AI was calculated as the percentage
of tumour cell apoptotic bodies per total num-
ber  of  tumour  cells  counted  for  each  case.
Tumour specimens was stratified, according to
AI, into ≤10% or >10%.
19
Statistical analysis
Kruskal-Wallis test was used to establish the
difference  for  nonparametric  independent
variables, and was applied to establish differ-
ences  among  the  ampullary  histotypes  for:
tumour local extension (T factor), nodal status
(N  factor),  differentiation  grade  and  hENT1
expression.  Mann-Whitney  test  was  used  to
establish the difference for two independent
samples, and was used to verify differences in
terms  of  hENT1  expression  and  PI  between
pancreaticobiliary  vs.  intestinal  or  unusual
types, and between intestinal vs. unusual type.
Furthermore, Mann-Whitney test was applied
to establish the relationship between hENT1
and AI. P values less than 0.05 were regarded
as statistically significant in two-tailed tests.
SPSS  software  (version  14.0.1,  2005,  SPSS
Inc.) was used for statistical analysis.
Results
Patients’ characteristics
The  main  clinicopathological  features  are
summarized in Table 1. The cohort consisted
of 41 patients with pathological diagnosis of
radically resected cancer of the ampulla (23
men and 18 women). The median age at diag-
nosis  was  63  years  (range  38-78).  Seven
patients  (17.1%)  were  classified  as  T1,  17
(41.5%) as T2, 15 (36.6%) as T3, and 2 (4.9%)
as T4. Eighteen (43.9%) patients had locore-
gional lymph node metastasis. A positive sta-
tistical correlation was found between T and N
factor (r=0.507; P=0.001).
According to histological criteria published
by  Albores-Saavedra,4 we  found  20  (48.8%)
intestinal-type carcinomas, 14 (34.1%) pancre-
aticobiliary-type  carcinomas,  and  7  (17.1%)
unusual-type carcinomas (4 undifferentiated, 1
signet ring, 1 clear cell and 1 small cell carcino-
ma). A significant difference in the differentia-
tion  grade  was  found  among  the  histotypes
(P=0.007). In particular, significant differences
were found between unusual-type vs. intestinal
and pancreaticobiliary (P=0.001 and P=0.003,
respectively),  while  no  difference  was  found
between  intestinal  vs.  pancreaticobiliary
(P=0.888). These results are consistent with
the  histological  classification  since  “unusual
type” is a subgroup including poorly differenti-
ated ampullary cancers. No significant differ-
ence  was  found  in  T  and  N  factors  among
ampullary carcinoma subtypes (Table 2). 
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Table 1. Patients’ characteristics.
Total number 41
Median age (range) 63 (38-78 ) years
Gender
Male vs. female  23 vs. 18 (56.1% vs. 43.9%)
T factor
T1 7 (17.1%)
T2 17 (41.5%)
T3 15 (36.6%)
T4 2 (4.9%)
N factor
Negative 23 (56.1%)
Positive 18 (43.9%)
Grade
Well differentiated 13 (31.7%)
Moderate differentiated 21 (51.2%)
Poor differentiated 7 (17.1%)
Histotypes
Intestinal 20 (48.8%)
Pancreaticobiliary 14 (34.1%)
Unusual 7 (17.1%)[page 168] [European Journal of Histochemistry 2010; 54:e38]
Human equilibrative nucleoside
transporter 1 immunostaing and
apoptosis indices
hENT1  immunostaining  was  normally
observed  in  the  cells  of  the  islets  of
Langerhans  and  lymphocytes,  and  used  as
internal  positive  control.  Tumour  cells  dis-
played  hENT1  staining  localized  both  to  the
cytoplasm and to the plasma membrane; peri-
tumoral stromal cells were constantly negative
(Figure 1), while normal intestinal epithelium
showed  focal  and  weak  positivity  in  the
Lieberkuhn crypts (data not shown). Among
the 41 tissue samples, 26 (63.4%) showed sig-
nificant hENT1 expression (intensity scores of
2+ and/or 3+ in more than 60% of tumour tis-
sue). AI was >10% in 12 (29.3%) ampullary
cancer specimens.
Human equilibrative nucleoside
transporter 1 and morphological
histotypes
Significant hENT1 expression was evident
in 17/20 (85%) intestinal, 7/14 (50%) pancre-
aticobiliary and 2/7 (28.6%) unusual carcino-
mas.  A  significant  statistical  difference  in
hENT1 expression was found among the histo-
types  (P=0.014).  In  particular,  a  significant
difference  was  found  between  intestinal  vs.
pancreaticobiliary types and between intestin-
al vs. unusual types; no difference was found
between pancreaticobiliary vs. unusual types
(Table 3). 
Proliferation indices, apoptosis
indices and others variables
In terms of PI, a significant statistical differ-
ence  was  found  between  intestinal  (median
40%; Inter Quartile Range [I.Q.R] 30-42.5%)
and  pancreaticobiliary  histotypes  (median
25%;  I.Q.R.  6.25-40%)  (P=0.009).  No  differ-
ence was found between unusual-types (medi-
an 15%; I.Q.R. 3-45%) and the other histotypes.
A  significant  statistical  positive  correlation
was found between AI and PI (P=0.036), while
no  association  was  found  between  AI  and
hENT1 expression, T factor, N factor or differ-
entiation grade.
Discussion
In the present study, we have demonstrated
that intestinal-type carcinoma of the ampulla
of Vater displays significantly higher levels of
hENT1 expression and higher PI than pancre-
aticobiliary type. Furthermore, a positive cor-
relation between PI and AI was also evident.
The  relationship  between  apoptosis  and  cell
proliferation,  also  reported  in  various  neo-
plasms, suggests a compensatory mechanisms
for these events (i.e., the higher number of
proliferating cells is reduced by higher levels of
apoptosis).
20-23 However, although PI is closely
correlated to AI and hENT1 expression  is cor-
related to higher PI,
16 no association was found
between hENT1 and AI. As a working hypothe-
sis, we propose that hENT1, by allowing nucle-
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Table 2. Differences in T, N and Grade factors among ampullary subtypes.
Histotype T factor P* N factor P* Grade P*
T1 T2 T3 T4 N0 N1 12 3
Intestinal 596 00.256 12 8 0.821 8 11 1 0.007
Pancreaticobiliary 255 2 7 7 5 81
Unusual 034 0 4 3 0 25
*Kruskal-Wallis test.
Figure  1.  Immunohistochemical  staining  of  ampullary  adenocarcinoma.  (A)  strong
immunostaining for hENT1 in intestinal type carcinoma. (B) Details of (A). (C) Negative
expression for hENT1 in pancreaticobiliary type carcinoma whereas adjacent lympho-
cytes (arrows) demonstrate staining and provide a positive internal control. (D) Details of
(C). (E) Only distinctly Ki67 (MIB-1) immunoreactive tumour cell nuclei were valued as
positive. (F) Strict criteria were used to define a cell as apoptotic: only positive TUNEL
stained with the presence of a condensed and often fragmented nucleus together with a
surrounding halo (arrowheads). Scale bars: A, C = 50 μm; B, D, E, F = 10 μm.
Table 3. Differences in hENT1 expression
among the histotypes.*
Intestinal    Pancreaticobiliary
Pancreaticobiliary P=0.03
Unusual P=0.006 P=0.361
*Mann-Whitney test.[European Journal of Histochemistry 2010; 54:e38] [page 169]
osides to enter the cells through the plasma
membrane, controls DNA synthesis and there-
fore  proliferation  activity,  without  directly
affecting  apoptotic  mechanisms.  Following
this hypothesis, our data suggest that hENT-1
expression  may  generate  an  imbalance
between  proliferation  and  apoptosis  (e.g.,
stimulating  proliferation  while  not  affecting
apoptosis),  playing  an  important  role  in  the
growth of tumour bulk.
Recent studies have suggested that different
histological types of ampullary carcinomas may
reflect  a  different  biological  behaviour.  For
example,  K-Ras  mutations  were  significantly
more frequent in intestinal than in the pancre-
aticobiliary types, and intestinal type adenocar-
cinomas showed p53 abnormalities more com-
monly  than  the  pancreaticobiliary  type.
24
Moreover, mucin 2 glycoprotein and cytokeratin
(CK) 20 are more intensely expressed in intes-
tinal than in pancreaticobiliary type, while CK7
is  more  expressed  in  pancreaticobiliary  than
intestinal  type.
25 Recently,  our  group  demon-
strated that COX-2 protein is significantly more
expressed in intestinal than pancreaticobiliary
type ampullary cancer.
26 The direct association
between hENT1 expression and tumour growth
here suggested gives a biological explanation
for the relationship between hENT1 and sur-
vival.
15In these terms, hENT1, by the function of
nucleoside  transporter,  would  represent  the
intrinsic cellular key to tumour growth, being
consequently  related  to  worse  prognosis  in
ampullary carcinoma. In conclusion, our results
support the concept of histogenetically different
types  of  ampullary  carcinomas,  providing  the
rationale for prospective clinical trials aimed at
examining the treatment efficacy by classifying
ampullary  carcinoma  using  histological  sub-
types. Moreover, our results suggest the key role
of hENT1 in tumour growth of ampullary carci-
noma. Characterization of these tumours based
on histopathology, immunohistochemistry and
molecular pathology may help to elucidate their
aetiology, to define different risk profiles, and to
program more tailored therapies.
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